LOGO
LOGO

Astria Awaits ALPHA-STAR Trial Data, Stock Up Over 80% In 2 Months, Is There More Room To Run?

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News
rttnewslogo20mar2024

Astria Therapeutics Inc. (ATXS), a biopharmaceutical company developing life-changing therapies for rare and niche allergic and immunological diseases, has a clinical trial catalyst to watch this quarter.

The company's lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein for the preventative treatment of Hereditary Angioedema (HAE), a rare genetic disorder characterized by severe, unpredictable, sometimes life-threatening swelling.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - May 04 – May 08, 2026

May 08, 2026 15:50 ET
Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.

Latest Updates on COVID-19